TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03600896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107
Description: Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~* 5 mcg/kg/dose for 3 doses~* 10 mcg/kg/dose for 3 doses~* 20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107
Description: Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~* 5 mcg/kg/dose for 3 doses~* 10 mcg/kg/dose for 3 doses~* 20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II.
Study: NCT03237520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy
Description: VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mCIMT
Description: Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
Study: NCT03046511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
Study: NCT01835600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP
Description: PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
Study: NCT04183634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine TTS (Test)
Description: Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine TTS (Test)
Description: Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupro (Reference)
Description: Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupro (Reference)
Description: Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.
Study: NCT01350141

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An infusion lasting approximately 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: An infusion lasting approximately 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: An infusion lasting approximately 60 minutes
Study: NCT02607657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg twice a day
Study: NCT01185743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 10mg od + placebo od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 10mg od + placebo od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: ziprasidone 40mg td
Study: NCT01231841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study: NCT05357937

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard physiotherapy program
Description: A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard physiotherapy program
Description: A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups
Study: NCT04250337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid
Description: Topical Corticosteroid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Corticosteroid
Description: Topical Corticosteroid
Study: NCT05398146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mathematical operations
Description: Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mathematical operations
Description: Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mathematical operations
Description: Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ball squeezing
Description: For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ball squeezing
Description: For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.
Study: NCT04456049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 40 mg oral tablets once daily for a maximum of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 40 mg oral tablets once daily for a maximum of 28 days.
Study: NCT01855997

Intervention type: DRUG
Intervention: Peg-IFN alfa-2a
Description: Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
Study: NCT04364022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: 2x 200mg/50mg, twice daily for 5 days (bid, PO)
Study: NCT05800483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healium
Description: web-based platform to elicit patients' preferences about prostate cancer treatment and designed for low health literature populations
Study: NCT01364545

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ketone ester drink
Description: Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo (carbohydrate containing) drink
Description: Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
Study: NCT03866434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD422
Description: Participants will receive 1 mg of SPD422 (2\*0.5 mg) capsule orally on Day 1 and 8 in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
Study: NCT01304251

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short-term fasting
Description: Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Healthy nutrition
Description: Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
Study: NCT00094497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptozotocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitotane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitotane
Study: NCT01475370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-501
Description: 1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose.
Study: NCT03735641

Intervention type: PROCEDURE
Intervention: Expanded Pedicled Deltopectoral Flap
Description: Expanded Pedicled Deltopectoral Flap is a type of surgical flap
Study: NCT02538471

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Drug
Description: Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
Study: NCT01185743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: ziprasidone 40mg td

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo td
Study: NCT05398146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ball squeezing
Description: For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: listening to music
Description: Children were allowed to listen to music with headphones during dressing changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: listening to music
Description: Children were allowed to listen to music with headphones during dressing changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: listening to music
Description: Children were allowed to listen to music with headphones during dressing changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kontrol grubu
Description: No application was made during dressing change in children. Routine dressing change of the clinic was applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kontrol grubu
Description: No application was made during dressing change in children. Routine dressing change of the clinic was applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kontrol grubu
Description: No application was made during dressing change in children. Routine dressing change of the clinic was applied.
Study: NCT00613288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo
Description: The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~1. Placebo (hypogonadism after leuprorelide injection)~2. Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~3. Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~4. No treatment.
Study: NCT00706225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene and conjugated estrogens
Description: Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
Study: NCT05496621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: 1st Stage Keele Start MSk tool translated into Turkish and its cultural adaptation, 2nd Stage Statistical analysis of reliability and validity of Turkish Keele start msk tool
Study: NCT04175301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Each hydrogen tablet contains 80 mg magnesium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matching placebo tablet also contains 80 mg magnesium
Study: NCT01337414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VMS diary booklet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT02100150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored solution 0.5% v/v in Water for Injection
Study: NCT03620838

Intervention type: DRUG
Intervention: oral contraceptive pill, oral progesterone
Description: ovarian endometrioma cyst excision

Intervention type: DRUG
Intervention: oral contraceptive pill, oral progesterone
Description: ovarian endometrioma cyst excision

Intervention type: DRUG
Intervention: oral contraceptive pill, oral progesterone
Description: ovarian endometrioma cyst excision
Study: NCT02508532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets
Study: NCT00883038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diabetic diet following the DNSG guidelines
Description: The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-fat vegetarian diet
Description: The low-fat vegetarian diet (\~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
Study: NCT04845724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Diet
Study: NCT01694602

Intervention type: BIOLOGICAL
Intervention: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
Description: Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
Study: NCT02826122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pai APP
Description: Prescription: Target 100 PAI Points per week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit APP
Description: Prescription: Target daily 10.000 steps
Study: NCT04307706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in six sessions. The duration of each session lasted on average 60-90 minutes. A session was held for each parent once a week.
Study: NCT00927355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician.
Study: NCT03485014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: EXPAREL 4 mg/kg
Study: NCT00641719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: Duloxetine 40 mg QD, PO, 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: Duloxetine 60 mg QD, PO, 1 year
Study: NCT02981381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEST-1
Description: The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEST-2
Description: The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NEST-2
Description: The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.
Study: NCT02672384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental examination and a point of care P. gingivalis test (Denka Seiken Co (Japan) )
Description: Dental examination Study exams (oral and blood sample collection)
Study: NCT04389502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CaPtyVa app
Description: The apps stores all the current local Clinical practice guidelines information related to CRC screening and surveillance and through its decision algorithms assist physicians in the screening process. In the screening function, CaPtyVa helps the physicians to classify patient´s according to their individual CRC risk and to determine how and when to start with screening tests. In the surveillance, function the app assist the physician in determining when to repeat the next colonoscopy according to guideline recommendation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: current physician knowledge on local current CRC screening and surveillance guidelines
Study: NCT00547287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
Study: NCT03062774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PB-119 injection
Study: NCT04028310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phonological
Description: * Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual-attention
Description: * Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks